Media headlines about Miragen Therapeutics (NASDAQ:MGEN) have trended somewhat positive on Friday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Miragen Therapeutics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 44.6758920916078 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million (americanbankingnews.com)
- Miragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment Research (americanbankingnews.com)
- Miragen Therapeutics (MGEN) vs. Its Peers Head-To-Head Contrast (americanbankingnews.com)
- -$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter (americanbankingnews.com)
- Miragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley Forecasts (americanbankingnews.com)
Several research firms have recently issued reports on MGEN. Jefferies Group began coverage on Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $19.00 price objective on shares of Miragen Therapeutics in a research note on Wednesday, March 28th. Deutsche Bank initiated coverage on Miragen Therapeutics in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 price objective for the company. Evercore ISI initiated coverage on shares of Miragen Therapeutics in a research report on Friday, March 9th. They set an “outperform” rating and a $19.00 target price for the company. Finally, Cann reissued a “buy” rating and set a $13.00 target price on shares of Miragen Therapeutics in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.31.
Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, March 14th. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%. The firm had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $1.22 million. sell-side analysts forecast that Miragen Therapeutics will post -1.17 EPS for the current year.
In other Miragen Therapeutics news, Director Bruce Booth bought 545,454 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average cost of $5.50 per share, with a total value of $2,999,997.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Adam Scott Levy acquired 9,090 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was purchased at an average cost of $5.50 per share, with a total value of $49,995.00. Following the acquisition, the insider now owns 10,540 shares in the company, valued at approximately $57,970. The disclosure for this purchase can be found here. 44.40% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Miragen Therapeutics (MGEN) Earns Media Sentiment Rating of 0.06” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/04/06/miragen-therapeutics-mgen-given-daily-news-sentiment-score-of-0-06/2029448.html.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.